|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00047541 |
|
Date of registration:
|
08/10/2002 |
|
Primary sponsor: |
|
|
Public title:
|
Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70
|
|
Scientific title:
|
Phase III Safety and Efficacy Study to Evaluate Combination IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertensive Patients C-01-70. |
|
Date of first enrolment:
|
February 2001 |
|
Target sample size:
|
|
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00047541 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Key inclusion & exclusion criteria
|
Adult subjects of either sex and any race with open-angle glaucoma or ocular hypertension;
visual acuity of 20/80 to 20/400 or better (Snellen equivalent) or logMAR visual acuity
not worse than 0.6. Clinically relevant ophthalmic or systemic conditions may be excluded.
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Ocular Hypertension
|
|
Open-Angle Glaucoma
|
|
Intervention(s)
|
|
Drug: Alcon Investigational Agent
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|